BridgeBio Pharma

View All

MyoKardia & Eidos purchase; Amgen's Aimovig; HCV discovery; Bharat Biotech's Covaxin
MyoKardia buyout; Eidos acquisition; Amgen’s Aimovig; HCV discovery; Bharat Biotech’s Covaxin

MyoKardia Buyout: BMS expands its cardiovascular portfolio for USD 13.1 Billion  Bristol Myers Squibb has bounty years in a go with its shares skyrocketing as it decides to go on an acquisition spree.  BMS has announced to acquire MyoKardia, a pharmaceutical company leveraging precision medicine to ...

Find More

Hereditary Transthyretin Amyloidosis Market | hATTR Market Size | hATTR
Unfolding The Folds Of Transthyretin

The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Million in 2017 and is anticipated to grow further in the forecast period 2020-30 owing to recent approvals and pipeline therapies.Among the 7MM geographies, the US accounted for the 54% share of the total hATTR ma...

Find More

BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M

BridgeBio bags USD 299 Million for genetic diseases BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical development. Several therapeutic areas are being taken under the consideration of the pharma. Also, th...

Find More

Business cocktail

Bayer and Berkeley Lights embark on a project to automate drug discovery Pharmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate antibody discovery and development of cell lines. Bayer and Berkeley Lights’ platform- Be...

Find More